[Neoadjuvant therapy of breast cancer using Newcastle disease virus]
| Autor: | V V, Keshelava, N Iu, Dobrovol'skaia, N L, Chazova, A M, Bershchanskaia, M V, Podol'skaia, T V, Garmarnik, N V, Mel'nikova |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Receptor ErbB-2 Newcastle disease virus Breast Neoplasms Middle Aged Cancer Vaccines Neoadjuvant Therapy Gene Expression Regulation Neoplastic Ki-67 Antigen Treatment Outcome Receptors Estrogen Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor Humans Female Tumor Suppressor Protein p53 Receptors Progesterone Aged Neoplasm Staging |
| Zdroj: | Voprosy onkologii. 55(4) |
| ISSN: | 0507-3758 |
| Popis: | The role of Newcastle disease virus and neoadjuvant therapy was assessed in 84 cases of breast cancer T1-4N0-2M0 (2005-2008). Combined use of the virus vaccine and chemotherapy (group A), therapy with the vaccine alone (group B) and chemotherapy regimen identical with that used in group A (group C) were compared. Histological pattern of tumor and stage were identified using expression of receptors of steroid hormones, oncoproteins Her2/neu and p53 as well as proliferation activity (marker Ki-67) before and after therapy. It was shown that the efficiency and safety of Newcastle disease virus (apathogenic strain La-Sotha) met specific immuno- and neoadjuvant therapy standards. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|